ERBB2 and breast cancer: Only patients with HER2-positive BC are selected for HER2-targeted therapies, although it has been reported that patients with BC exhibiting low (IHC 1+) or moderate HER2 expression (IHC 2+) without HER2 gene amplification may benefit from treatment with trastuzumab deruxtecan, a potent ADC.4